L40 L40.5
Conditions
Interventions
Group 1: Patients with Psoriasis were observed during the Biologic Therapy
Patients were observed during 24 months. After the initiation visit, patient data was gathered at 3,6,9,12,18 and 24 months
Sponsors
Abbott GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: moderate to severe psoriasis (with PASI, BSA or DLQI > 10)
Exclusion criteria
Exclusion criteria: Any other skin diseases that could interfere with the evaluation of psoriasis severity or other forms of psoriasis than plaque-type, onychomycosis, latent or active tuberculosis, hepatitis B and C, HIV infection as well as inability to understand the questionnaires and adhere to the trial procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Efficiency of TNF-blocker therapy on nail psoriasis • Measure of the following clinical parameters: PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area) and NAPSI (Nail Psoriasis Severity Index) • Measure of HAQ (Health Assessment Questionnaire) in PSA Patients | — |
Secondary
| Measure | Time frame |
|---|---|
| • Explorative measurements of the changes in health related quality of life • Measure of the daily burden and non-productivity Measure of DLQI (Dermatology Life Quality Index) | — |
Countries
Germany
Contacts
Public ContactSusana Gomis-Kleindienst
AbbVie Deutschland GmbH & Co. KG
Outcome results
None listed